Glaxo Makes Patient-Level Data Available from Drug Trials

0
132

After years of controversy over access to trial data, GlaxoSmithKline announced today that it will make patient-level data from its drug trials available to researchers. “This doesn’t sound like transparency to me,” said MIA blogger Carl Elliott, a professor at the Center for Bioethics at the University of Minnesota, “It sounds like a PR tactic. If I suspect that researchers on a GSK-funded trial have rigged the design or cooked the data, is this ‘independent panel of experts’ going to give me access?”

Press Release →

Glaxo Peels Back Curtain On Drug Data (Pharmalot)
Glaxo Opens Door to Data on Research (NY Times)

Previous articleStress and the City
Next articleOxytocin Focuses Attention on Social Cues: A Mixed Blessing
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected]

LEAVE A REPLY